#AGS22: Offering the Latest in Medication Use, COVID-19 Research, Dementia Treatments, Health Equity & More

The worlds of work, education, science, and networking have changed in response to the COVID-19 pandemic, and the AGS is evolving with them. In the past year, we have seen many innovations in research methods and the ways we provide care, such as the approval of COVID-19 vaccines which have prevented serious illness and treatments that have offered hope for those who become sick. As a society, we have spent time asking the important questions about the ways social factors can intersect with our health and care outcomes, and how individual and structural biases can affect those receiving and providing care.

We are looking forward to building off the momentum from these breakthroughs at our AGS Annual Scientific Meeting (#AGS22) this May 12-14, 2022 in Orlando, FL. #AGS22 will address the educational needs of geriatrics professionals from all disciplines, offering continuing education sessions such as invited symposium, meet-the-expert sessions, workshops, updates in geriatrics research, and advocacy information. #AGS22 will also offer post-meeting recordings for a selection of program sessions, available for those unable to travel to Orlando this May. We hope to see you in Orlando.

Browse some highlights from #AGS22's program schedule and visit **Meeting.AmericanGeriatrics.org** to register.

Updates to the AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults

Updated every 3 years, the AGS Beers Criteria® are focused on preventing adverse drug events and serve as an important tool for systems and individuals who seek to ensure high-quality health care for older adults (OAs). Originally conceived by the late Mark Beers, MD, the Beers Criteria catalogue medications that place OAs at an elevated risk for adverse drug events due to the physiological changes of aging or concurrent conditions. This program will present an overview of the updated 2022 criteria.

Henderson State-of-the-Art Lecture: Achieving Diversity in Study Populations: The Importance of Community Engagement

Sharon Brangman, MD, AGSF will discuss the importance of designing research protocols that are inclusive of OAs who have been historically excluded or exploited in medical research. Dr Brangman will present a model of community engagement that includes employing a community research liaison and a research accelerator to increase diversity in aging research.

Dismantling Racism Brick by Brick: How Should Health Care Organizations Respond to Racism Against Health Care Workers?

This symposium considers how health care organizations should respond to overt racism expressed by patients against health care professionals, from the perspective of organizational leadership, including executive, legal, and policy experts.

Evidence-based Prescribing and Deprescribing in the Mild, Moderate & Late-Stages of Dementia.

Alzheimer disease and related dementias present distinct medical, behavioral, and psychosocial challenges during the mild, moderate, and late stages. Those living with dementia are especially in need of individualized care, and the challenging decision to prescribe and deprescribe medications often falls on geriatrics health professionals across a variety of settings. Evidence for the starting and discontinuing of medications using the 5M's framework as a guide will be provided over the course of 3 sessions.

Long-Term Pulmonary, Cognitive, and Psychiatric Outcomes of COVID-19

Presenters will review the most updated understanding of the biological impact of SARS-CoV-2 infection on various organ systems and share findings from their longitudinal cohort studies, including hospitalized older and younger adults with and without critical illness. Presenters will review pulmonary, cognitive, and psychiatric symptoms, summarizing what clinicians should know about treating unique long-term health concerns.

Update on Alzheimer Disease Diagnosis, Therapeutics

In June 2021, the FDA approved Biogen's drug aducanumab for use in treating people with Alzheimer disease. This session will review the evidence and controversies surrounding aducanumab, including the implications for other pharmaceutical companies to potentially seek accelerated FDA approval for anti-amyloid therapy based on surrogate (biomarker) endpoints. Attendees will learn how best to choose appropriate patients for aducanumab and how to use the treatment. There will also be a discussion about precision medicine being increasingly applied to OAs in determining their risk of future dementia and other neurodegenerative diseases. ∎